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Abstract Cystatins A and C were both shown to inhibit
cathepsin B by a two-step mechanism, involving an initial weak
interaction followed by a conformational change. Disruption of
the major salt bridge anchoring the occluding loop of cathepsin B
to the main body of the enzyme by mutation of His110 to Ala
converted the binding to an apparent one-step reaction. The
second step of cystatin binding to cathepsin B must therefore be
due to the inhibitor having to alter the conformation of the
enzyme by displacing the occluding loop to allow a tight complex
to be formed. Cystatin A was appreciably less effective in
displacing the loop than cystatin C, resulting in a considerably
lower overall inhibition rate constant. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Cystatins are inhibitors of papain-like cysteine proteinases
and act by binding tightly to the active site cleft of the enzyme
(reviewed in [1^5]). The cystatin superfamily contains three
subfamilies. Cystatins of family I, also termed ste¢ns, are
single domain proteins of about 100 amino acids, having no
disulphide bonds. The inhibitors of family II are somewhat
longer, about 120 amino acids, and have two internal disul-
phide bonds. Cystatins of family III, termed kininogens, are
high molecular mass, multi-domain glycoproteins.
Most papain-like cysteine endoproteinases have an open,
easily accessible active site [5^7]. The kinetics of cystatin in-
hibition of these enzymes is consistent with a simple, one-step
reaction mechanism [8^14], in agreement with computer dock-
ing studies [15]. In contrast, the dominating lysosomal cys-
teine proteinase, cathepsin B, has an ‘occluding loop’ that
partially blocks the active site, thereby being responsible for
the dipeptidase activity of this enzyme [16,17]. Studies of the
kinetics of binding of cystatin C, a family II cystatin, to ca-
thepsin B have indicated that the reaction occurs in two steps,
an initial weak binding being followed by a conformational
change in the second step [18]. It has been proposed that this
change is due to the necessity for the inhibitor to alter the
conformation of the enzyme by displacing the occluding loop
so that a tight complex can be formed [16,18].
In this work we show that cystatin A (also called ste¢n A),
a family I inhibitor, also binds to cathepsin B by a two-step
reaction mechanism with a conformational change in the sec-
ond step, consistent with this mechanism being common for
all cystatins. Moreover, we show that increasing the mobility
of the occluding loop of cathepsin B by disruption of the salt
bridge between His110 and Asp22 through mutation of
His110 to Ala [16,19] transforms the two-step binding of
both cystatins A and C to an apparent one-step reaction.
This observation strongly supports the notion that the tran-
sition between the initial weak and ¢nal tight cathepsin B^
cystatin complexes involves the inhibitor dislocating the oc-
cluding loop of cathepsin B, thereby inducing a conforma-
tional change in the enzyme.
2. Materials and methods
2.1. Proteins
Human recombinant cystatins A and C and papain (v95% active)
were produced and isolated as described earlier [12,20^23]. The inac-
tive papain derivative, S-(methylthio-)papain, was prepared as in pre-
vious work [23]. Human recombinant cathepsin B and the C29A and
H110A/C29A mutants of the enzyme, constructed by site-directed
mutagenesis, were expressed as proenzymes [17,18]. The wild-type
proenzyme was activated as described previously [17,18]. C29A-pro-
cathepsin B was processed by incubation with a catalytic amount of
wild-type human cathepsin B for 4 h at 37‡C in 20 mM sodium
acetate, 1 mM dithiothreitol (DTT), pH 5.0, resulting in complete
conversion to the mature form. The wild-type enzyme was then in-
activated by addition of [N-(L-3-trans-carboxyoxiran-2-carbonyl)-L-
leucyl]amido-4-guanidobutane to 15 WM. Processing of H110A/
C29A-procathepsin B occurred on storage of the puri¢ed proenzyme
for 2 months at 4‡C in 20 mM sodium acetate, pH 4.7. The processed
proteins were puri¢ed by ion-exchange chromatography on CM Se-
pharose Fast Flow (Amersham Pharmacia Biotech, Uppsala, Swe-
den).
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Protein concentrations were obtained by absorption measurements
at 280 nm. The molar absorption coe⁄cients used were: 8800 M31
cm31 for cystatin A [12], 11 100 M31 cm31 for cystatin C [10], 55 900
M31 cm31 for papain and S-(methylthio-)papain [23] and 63 000 M31
cm31 for wild-type cathepsin B and its two mutants [18].
Protein homogeneity was checked by sodium dodecyl sulphate^
polyacrylamide gel electrophoresis (SDS^PAGE) under reducing and
non-reducing conditions with the tricine bu¡er system [24].
2.2. Binding stoichiometries
The fraction of active inhibitor in the cystatin A and C preparations
was checked by stoichiometric titrations, monitored by the £uores-
cence decrease induced by the binding of 1 WM papain with inhibitor
[23]. The fraction of protein in the recombinant cathepsin B prepara-
tions that was active in binding cystatins was assessed by analogous
titrations of 1 WM enzyme with cystatin C. The titrations of the wild-
type enzyme were monitored by activity measurements [18] and those
of the inactive C29A and H110A/C29A mutants by the increase in
tryptophan £uorescence accompanying the interaction with cystatin C
(see Section 3).
2.3. A⁄nity and kinetics of inhibition of wild-type cathepsin B
The inhibition constant, Ki, for the interaction of cystatin A with
wild-type human cathepsin B was determined from the equilibrium
rates of cleavage of the £uorogenic substrate, carbobenzoxy-L-arginyl-
L-arginine 4-methylcoumaryl-7-amide (Peptide Institute, Osaka, Ja-
pan), at di¡erent concentrations of the inhibitor [25,26]. The overall
association rate constant, kon, for the same interaction was evaluated
under pseudo-¢rst-order conditions by continuous measurements of
the loss of enzyme activity against the £uorogenic substrate by con-
ventional £uorometry [25].
2.4. Stopped-£ow kinetics
The rates of association of cystatin A with wild-type cathepsin B
and of cystatins A and C with the C29A-cathepsin B (cathepsin B
variant in which Cys29 is replaced by Ala) and H110A/C29A-cathep-
sin B (C29A-cathepsin B variant in which His110 is replaced by Ala)
mutants were analysed in a SX-17 MV stopped-£ow £uorimeter (Ap-
plied Photophysics, Leatherhead, UK) by monitoring the resulting
tryptophan £uorescence change [18]. The molar ratio of cystatin to
the fraction of the cathepsin B variants active in binding inhibitor was
at least 10-fold. Observed pseudo-¢rst-order rate constants, kobs, were
obtained by non-linear least-squares regression of the progress curves.
2.5. Dissociation kinetics
The rates of dissociation of the complexes of cystatins A and C with
the C29A-cathepsin B mutant were measured by displacement of the
inhibitor from 1 WM complex with an excess (2.5^7 WM) of S-(meth-
ylthio-)papain [12], which forms much tighter complexes with both
cystatins than cathepsin B does [10,12,25]. The overall dissociation
rate constants, koff , were obtained by non-linear least-squares regres-
sion analysis of the exponential decrease of tryptophan £uorescence
accompanying formation of the complexes between the liberated cys-
tatins and S-(methylthio-)papain. The £uorescence decrease is due to
these complexes having lower £uorescence than the corresponding
complexes with cathepsin B [10,12,18].
2.6. Experimental conditions
All experiments were carried out at 25.0 þ 0.2‡C. Wild-type cathep-
sin B was activated with 1 mM DTT for 5 min before measurements
and analysed in 50 mM Mes, 100 mM NaCl, 0.5 mM DTT, 0.1 mM
EDTA, 0.1% (w/v) poly(ethylene glycol) 6000, pH 6.0. The experi-
ments with C29A-cathepsin B and H110A/C29A-cathepsin B were
performed in the same bu¡er without DTT.
3. Results
3.1. Homogeneity and activity of the proteins
As in earlier work, recombinant cystatins A and C and
recombinant wild-type cathepsin B were s 97% homogeneous
in SDS^PAGE [17,20,22]. In further accord with this work,
the two cystatins were fully active in binding to papain,
whereas wild-type cathepsin B was 48 þ 1% (range, n = 2) ac-
tive in binding to cystatin C.
In the present work, the mobility of the occluding loop of
cathepsin B was increased by mutation of His110 to Ala,
disrupting the salt bridge to Asp22 [16,19]. Isolation of su⁄-
cient amounts of a stable form of this mutant required that
autoproteolysis be prevented by a concurrent mutation of the
active site Cys29 to Ala (Krupa and Mort, in preparation).
The C29A-cathepsin B control and H110A/C29A-cathepsin B
were s 97% andV80% homogeneous in SDS^PAGE, respec-
tively. In the latter case, the unprocessed proenzyme, which is
inactive and unable to bind inhibitors [27^29] and therefore
should not in£uence the analyses, was the major contaminat-
ing protein. Titrations with cystatin C showed that the C29A
and H110A/C29A mutants were 97 þ 4% (S.E.M., n = 6) and
79 þ 2% (range, n = 2) active in binding cystatins, in good
agreement with their purity in SDS^PAGE.
3.2. Kinetics of cystatin C binding
The kinetics of binding of cystatin C to C29A- or H110A/
Fig. 1. kobs for the binding of cystatin C (A) or cystatin A (B) to
C29A-cathepsin B (a) or H110A/C29A-cathepsin B (b) as a func-
tion of inhibitor concentration. The vertical bars represent the stan-
dard errors of the mean calculated from 10^20 individual measure-
ments. Error bars not seen lie within the dimensions of the symbols.
The solid lines represent non-linear least-squares regression ¢ts to
the hyperbolic equation for the two-step mechanism in Scheme 1
[30] in the case of C29A-cathepsin B and linear least-squares regres-
sion ¢ts in the case of H110A/C29A-cathepsin B.
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C29A-cathepsin B were monitored under pseudo-¢rst-order
conditions by the V15% increase in tryptophan £uorescence
accompanying the interaction with either enzyme form. All
progress curves were well ¢tted to a single exponential func-
tion, giving kobs. As in similar previous studies with wild-type,
active cathepsin B [18], kobs for the binding of cystatin C to
the C29A-cathepsin B control varied hyperbolically with the
inhibitor concentration (Fig. 1A). This behaviour is character-
istic of a two-step binding mechanism with a conformational





In this mechanism, a weak complex (PI) between proteinase
(P) and inhibitor (I) in a rapid equilibrium, characterised by
the dissociation constant K1, is formed in the ¢rst step, fol-
lowed by a conformational change with the rate constants k2
and k32 in the second step to form the ¢nal complex (PI*).
Fitting of the data for the binding of cystatin C to C29A-
cathepsin B to the equation for this mechanism [30] gave
values for K1 and k2 (Table 1). However, k32, which in
this mechanism is equal to koff and is given by the intercept
on the ordinate, was too low to be determined. Instead, koff
was measured by displacing the inhibitor from the complex by
an excess of a tight-binding, inactive papain derivative (Table
1). Both K1 and k2, as well as kon, calculated from the initial
slope, i.e. as k2/K1 [30], were comparable to the values for
the binding of cystatin C to active cathepsin B (Table 1).
However, koff was V¢ve-fold higher than for the binding to
the active enzyme, thereby being mainly responsible for a
somewhat higher overall dissociation equilibrium constant
(Kd), calculated as koff /kon (Table 1).
Contrary to what was observed for the C29A-cathepsin B
control, kobs for the binding of cystatin C to the H110A/C29A
mutant increased linearly with the inhibitor concentration up
to the highest concentrations that could be reached with the
amounts of protein available (Fig. 1A). This behaviour is in-
dicative of a one-step binding reaction, although it cannot be
excluded that it re£ects only the initial, approximately linear
portion of a hyperbolic curve for a two-step reaction. How-
ever, in the latter case both K1 and k2 must be appreciably
higher than for the binding to the C29A-cathepsin B control,
simulations indicating values for K1 of E200 WM and for k2
of E200 s31 being compatible with the data. The value of
kon, which is the only parameter that can be derived from the
linear kobs dependence, was similar to those for the binding of
cystatin C to active cathepsin B and the C29A mutant (Table
1).
3.3. Kinetics of cystatin A binding
Attempts to analyse the stopped-£ow kinetics of cystatin A
binding to wild-type, active cathepsin B, which have not been
previously investigated, were unsuccessful because a 9 4%
£uorescence decrease due to complex formation could not
be separated from a concurrent slow decrease that most likely
was caused by photodecomposition. The binding therefore
could only be characterised by monitoring enzyme inhibition
in the presence of a £uorogenic substrate by conventional
£uorometry (Table 1). The measured Ki and kon and calcu-
lated koff values were comparable to those similarly obtained
for the interaction of cystatin A with human liver cathepsin B
[12].
The kinetics of binding of cystatin A to C29A- or H110A/
C29A-cathepsin B could be monitored by an exponential
V5% increase in tryptophan £uorescence. As in the case of
cystatin C, kobs for the binding of cystatin A to C29A-cathep-
sin B showed the hyperbolic dependence on inhibitor concen-
tration characteristic of a two-step binding mechanism with a
conformational change occurring in the second step (Fig. 1B;
Scheme 1). However, K1 and k2 di¡ered appreciably from
those for cystatin C binding (Table 1). K1 was thus Vfour-
fold higher and k2 almost 100-fold lower, resulting in a
V300-fold lower kon. The latter value was Vsix-fold lower
than that for the interaction of cystatin A with the active
enzyme. koff , again undeterminable by stopped-£ow kinetics
and instead measured by displacement experiments, was com-
parable to the value for the complex with active cathepsin B
(Table 1). The somewhat higher Kd for the binding of cystatin
A to C29A-cathepsin B than to the active enzyme (Table 1)
was thus due mainly to the lower kon.
In further agreement with the experiments with cystatin C,
kobs for cystatin A binding to H110A/C29A-cathepsin B in-
creased linearly with cystatin concentration (Fig. 1B), again
re£ecting a transformation to a one-step binding mechanism
or a substantial increase in both K1 and k2 of the two-step
mechanism. Simulations indicated that K1E500 WM and
k2E10 s31 would be required to account for the observed
linear dependence in this case. The H110A mutation thus
caused at least V10-fold increase in k2. kon obtained from
the linear kobs dependence wasV¢ve-fold higher than that for
Table 1
Kinetic and equilibrium constants for the interaction of recombinant human cystatins C and A with recombinant human wild-type cathepsin B
and its C29A and H110A/C29A mutants
Inhibitor Cathepsin B form K1 (WM) k2 (s31) kon (M31 s31) 104Ukoff (s31) Kd (nM)
Cystatin C wild-type 48 þ 10 118 þ 11 2.4U106a 6.7 þ 0.2 0.28b
C29A 65 þ 10 90 þ 10 1.3U106a 34 þ 3 2.6b
H110A/C29A (0.88 þ 0.01)U106 ND ND
Cystatin A wild-type ND ND (2.45 þ 0.05)U104 0.5c 2.1 þ 0.1
C29A 285 þ 35 1.2 þ 0.1 4.2U103a 1.2 þ 0.1 29b
H110A/C29A (1.98 þ 0.05)U104 ND ND
Measured values are given with standard errors of the mean, derived by linear or non-linear regression of the plots in Fig. 1 and similar plots
or, in the case of koff , obtained from six and three individual displacement experiments with cystatin C and cystatin A, respectively. Calculated
values are given without errors. The values for the binding of cystatin C to wild-type cathepsin B are taken from previous work [18]. ND, not
determined.
aCalculated as k2/K1.
bCalculated as koff /kon.
cCalculated as konUKd.
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cystatin A binding to the C29A-cathepsin B control but sim-
ilar to that for the binding to the active enzyme (Table 1).
4. Discussion
The aim of this work was to characterise the e¡ects of
increasing the mobility of the occluding loop of cathepsin B
on the two-step kinetics of inhibition of the enzyme by cys-
tatins. To this end, the major salt bridge that anchors the loop
to the main body of cathepsin B was disrupted by mutation of
His110 [16,19]. However, because of the decreased stability of
this mutant, the enzyme was inactivated by mutation of the
active site. Cystatin C bound to the Cys29 to Ala control
mutant in a similar manner as to active cathepsin B, i.e. by
a two-step mechanism with a comparable a⁄nity of the ¢rst,
weak binding step, K1, and a comparable forward rate con-
stant of the conformational change in the second step, k2
(Scheme 1). Only the reverse rate constant of the second
step, k32, was somewhat increased, indicating that Cys29
may contribute slightly to the stabilisation of the conforma-
tionally altered state. A corresponding comparison of cystatin
A binding to the inactivated and active cathepsin B forms was
not possible, as a low £uorescence change and a pronounced
photodecomposition precluded stopped-£ow analyses of the
interaction of this cystatin with active cathepsin B. However,
the somewhat higher overall association rate constant, kon,
determined by conventional inhibition kinetics is consistent
with slight changes of either or both of K1 and k2, although
in this case k32 was essentially una¡ected. Nevertheless, it is
apparent that mutation of Cys29 of cathepsin B to Ala only
minimally a¡ects the interactions of cystatins with the en-
zyme.
In a previous study it was suggested that the conformation-
al change occurring with the rate constant k2 in the second
step of cystatin C binding to cathepsin B involves the inhib-
itor displacing the occluding loop of the enzyme [18]. The
present work provides compelling evidence for this proposal.
Increasing the mobility of the occluding loop of cathepsin B
by release of loop anchoring thus was found to markedly alter
the mode of binding of both cystatins A and C to the enzyme,
so that no second step could be discerned. The increased
£exibility of the loop thus must have led to cystatin binding
in only a single step, as is apparent for cysteine proteinases
having easily accessible active sites, like papain [8^14], or to
both K1 and k2 of the two-step mechanism having been
substantially increased. The ¢rst alternative is consistent
with the loop having become su⁄ciently mobile so as not to
interfere with the inhibitor entering the active site cleft of the
proteinase, whereas the second alternative would mean that
the increased mobility of the loop has greatly facilitated its
being pushed aside by the inhibitor. Both alternatives strongly
indicate that the conformational change in the second step of
cystatin binding to cathepsin B with intact loop anchoring
occurs in the enzyme and is due to the inhibitor having to
dislocate the loop to allow a tight complex to be established.
This dislocation is made possible by the initial weak interac-
tion of the cystatin with the enzyme, in which the N-terminal
region of the inhibitor may play an important role
[25,26,31,32].
Both cystatins C and A were shown in this work to bind to
cathepsin B by a two-step mechanism. This behaviour indi-
cates that a conformational change in the enzyme, due to the
occluding loop being pushed aside by the inhibitor, is a com-
mon feature of the inhibition of cathepsin B by cystatins.
However, the kinetics of this change di¡ered markedly for
the two inhibitors. In particular, the considerably lower for-
ward rate constant of the conformational change, k2, for
cystatin A binding indicates that this inhibitor is much less
e¡ective in displacing the occluding loop than cystatin C.
Moreover, this lower rate of loop displacement is the major
reason for cystatin A inhibiting cathepsin B with a consider-
ably lower overall rate constant, kon, than cystatin C.
Although all cystatins thus presumably need to move the oc-
cluding loop of cathepsin B out of the way to gain access to
the active site of the enzyme, their ability to do so apparently
varies considerably.
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